Nebenwirkungen · Onivyde pegylated liposomal (previously Onivyde)
ONIVYDE pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion · Abschnitt 4.8 · PDF-Seite 16
HOS-135486 · Präparat HOS-097714
ONIVYDE pegylated liposomal in combination with oxaliplatin, 5-fluorouracil and leucovorin: In NAPOLI-3, renal impairment occurred in 0.3% of patients and was of Grade 3 or 4, renal failure occurred with Grade 1 to 4 in 0.5% of patients, among them 0.3% was Grade 3 or 4, acute kidney injury occurred with Grade 1 to 4 in 1.1% of patients, among them 0.8% were of Grade 3 or 4 in patients receiving NALIRIFOX. Blood creatinine increased occurred with all Grade 1 to 4 in 1.4% of patients, among them, 0.3% was Grade 3 or 4, creatinine renal clearance decreased occurred with Grade 1 or 2 in 0.3% of patients receiving NALIRIFOX. There was one case (0.3%) of renal failure with a fatal outcome in the NALIRIFOX arm.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-11-29T09:48:00Z · SHA-256 6fe241cd32f9f9d3c8592da7ea124a85ef29388269021487b0409971bc580040 · Passage 7ac36bbb4d8eabc1ef293b692e78dda391fcce8fd690c93682d7ca4b10992a82 · Zeichen 16633–17347 im Abschnitt